Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec with CLAG in Relapsed or Refractory AML
NCT00955916Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), sponsored by Moffitt Cancer Center. Started Aug 2009; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00955916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00955916.